MYCN overexpression has been reported in haematologic malignancies, such as lymphoma,27 chronic lymphocytic leukaemia (CLL) 28 and paediatric T‐ALL,29 and it is considered a well‐established marker of a poor prognosis in these diseases. This evidence concerns the gene MYCN and acute lymphoblastic leukemia.